Talis Biomedical to Announce First Quarter 2021 Financial Results on May 11, 2021
Talis Biomedical Corporation (TLIS) announced that it will release its financial results for Q1 2021 after market close on May 11, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Talis Biomedical Corporation (TLIS) announced that it will release its financial results for Q1 2021 after market close on May 11, 2021. A conference call will follow at 1:30 p.m. PT to discuss these results. The call can be accessed via telephone, with a live and archived webcast available on the company's investor website. Talis focuses on developing innovative molecular diagnostic tests for infectious diseases, aiming to provide accurate and rapid testing solutions, including its Talis One platform for COVID-19.
Details
News Market Reaction – TLIS
The recorded move for TLIS in the trading session of this news was -0.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the first quarter after market close on Tuesday, May 11, 2021. Talis will host a conference call, beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss financial and operational results.
Interested parties may access the live call via telephone by dialing 833-715-1329 for participants in the U.S. or Canada and 430-775-1933 for international callers, using conference ID 7657867. A live and archived webcast of the event can be accessed via the News & Events page of the investor section of Talis Biomedical’s website at www.talis.bio.
About Talis Biomedical
Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost and rapid molecular testing for infectious diseases at the point-of-care, beginning with COVID-19. The company is developing Talis One, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. Talis is headquartered in Menlo Park, California. For more information, please visit talis.bio.
Contact
Media & Investors
Emily Faucette
ir@talisbio.com
415-595-9407
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.